Cardiovascular Diseases From Molecular Pharmacology to Evidence-Based Therapeutics.

Detalles Bibliográficos
Autor principal: Li, Y. Robert
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Newark : John Wiley & Sons, Incorporated, 2015.
Colección:New York Academy of Sciences Ser.
Temas:
Electronic books.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Title Page
  • Copyright Page
  • Contents
  • Preface
  • List of Abbreviations
  • Unit I General Introduction
  • Chapter 1 Introduction to Cardiovascular Diseases
  • 1.1 Overview
  • 1.2 Definition of Cardiovascular Diseases
  • 1.3 Classification of Cardiovascular Diseases
  • 1.3.1 Classification Based on Anatomical Location
  • 1.3.2 Classification Based on the Involvement of Atherosclerosis
  • 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification
  • 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases
  • 1.4.1 NCDs and Cardiovascular Diseases: The Global Status
  • 1.4.2 The Status of Cardiovascular Diseases in the United States
  • 1.4.3 The Status of Cardiovascular Diseases in China
  • 1.5 Risk Factors of Cardiovascular Diseases
  • 1.5.1 Classification of Cardiovascular Disease Risk Factors
  • 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact
  • 1.6 Prevention and Control of Cardiovascular Diseases
  • 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level
  • 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases
  • 1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health
  • 1.6.4 US DHSS "Million Hearts" Initiative
  • 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments
  • 1.7.1 Cardiovascular Risk Prediction
  • 1.7.2 Evidence-Based Treatments
  • 1.8 Summary of Chapter Key Points
  • 1.9 Self-Assessment Questions
  • References
  • Chapter 2 Introduction to Principles of Pharmacology
  • 2.1 Overview
  • 2.2 Definitions and History
  • 2.2.1 What Is Pharmacology?
  • 2.2.2 Definitions of Related Terms
  • 2.2.3 A Brief History of Pharmacology
  • 2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology
  • 2.3.1 Drug Names, Sources, Preparations, and Administration
  • 2.3.2 Pharmacokinetics
  • 2.3.3 Pharmacodynamics
  • 2.3.4 Drug Toxicity
  • 2.3.5 Pharmacogenetics and Pharmacogenomics
  • 2.4 Principles of Drug Discovery, Development, and Regulation
  • 2.4.1 Definitions
  • 2.4.2 The Paradigm of Drug Creation and Survival
  • 2.4.3 The FDA Drug Review and Approval Process
  • 2.5 Pharmacology Subspecialties
  • 2.6 Introduction to Cardiovascular Pharmacology
  • 2.6.1 Definition and Scope
  • 2.6.2 New Developments and Challenges
  • 2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases
  • 2.6.4 Polypill for the Management of Cardiovascular Diseases
  • 2.6.5 Protein Therapeutics of Cardiovascular Diseases
  • 2.6.6 Gene Therapy of Cardiovascular Diseases
  • 2.6.7 Stem Cell Therapy of Cardiovascular Diseases
  • 2.7 Summary of Chapter Key Points
  • 2.8 Self-Assessment Questions
  • References
  • Unit II Dyslipidemias
  • Chapter 3 Overview of Dyslipidemias and Drug Therapy
  • 3.1 Introduction
  • 3.2 Lipoprotein Metabolism
  • 3.2.1 Definition, Structure, and Classification of Lipoproteins

Ejemplares similares